arrow
B

Bruce L. Innis

path
H指数:74
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and Immunogenicity of an Additional Dose of Thailand Government Pharmaceutical Organization (GPO) Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Administered After Primary Vaccination with HXP-GPOVac or BNT162b2: An Open-Label Phase II Extension Trial in Thai Adults

泰国政府制药组织(GPO)NDV-HXP-S灭活COVID-19疫苗(HXP-GPOVac)追加剂量接种的安全性和免疫原性:一项在泰国成年人中进行的开放标签II期扩展试验(在HXP-GPOVac或BNT162b2基础免疫后接种)

2026-07-290
OA
Safety and Immunogenicity of a Locally Produced Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Compared with BNT162b2: A Phase II Randomized, Controlled, Double-Blind Noninferiority Trial in Thai Adults

泰国国产灭活NDV-HXP-S COVID-19疫苗(HXP-GPOVac)与BNT162b2的安全性和免疫原性比较:一项在泰国成人中进行的II期随机、对照、双盲非劣效性试验

2026-05-300
OA
One year follow up of phase 1/2 randomized, placebo controlled trial of NDV-HXP-S vaccine in Thailand

在泰国进行的NDV-HXP-S疫苗1期/2期随机、安慰剂对照试验的一年随访研究

2025-11-250
OAAI
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil

重组新城病病毒灭活疫苗表达SARS-CoV-2刺突蛋白的安全性及免疫原性:巴西随机疫苗对照的I期ADAPTCOV试验结果

VACCINE
IF3.5
2025-04-010
PRE
Measles-Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and Considerations

麻疹-风疹微阵列贴片III期临床试验方案:提案与考量

2024-11-061
OAAI
Influenza A(H7N9) Pandemic Preparedness: Assessment of the Breadth of Heterologous Antibody Responses to Emerging Viruses from Multiple Pre-Pandemic Vaccines and Population Immunity

甲型流感 (H7N9) 大流行的防备: 评估对来自多种大流行前疫苗和人群免疫的新兴病毒的异源抗体反应的广度

2022-11-015
OAAI
Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial
2022-07-0114
OAAI
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial
2022-03-0127
OAAI
A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses
2021-10-2757
OAAI
Association Between Hemagglutination Inhibition Antibody Titers and Protection Against Reverse-Transcription Polymerase Chain Reaction-Confirmed Influenza Illness in Children 6-35 Months of Age: Statistical Evaluation of a Correlate of Protection
2021-09-255
OAAI
Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial
2021-06-0120
OAAI
Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model

基于嵌合血凝素的减毒活疫苗在临床前雪貂模型中赋予针对甲型流感病毒的持久保护性免疫

2021-01-1123
OAAI
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial
2020-12-07231
OAAI
Immunagenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial
2020-01-01115
OAAI
Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts

大流行性流感病毒疫苗可增强成年和儿科人群的血凝素茎特异性抗体反应

2019-12-0623
OAAI
Prevention of vaccine-matched and mismatched influenza in children aged 6-35 months: a multinational randomised trial across five influenza seasons
2018-05-0151
OAAI